Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form ...

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial ...

(RTTNews) - Merck & Co Inc. (MRK), Thursday said it has decided to stop the Phase 3 HYPERION study evaluating Winrevair in pulmonary arterial hypertension (PAH). The HYPERION study is designed to ...

(NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial hypertension ...